A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Inclusion Criteria:

Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer.
Has metastatic disease that has progressed during or following previous treatment appropriate for the disease type
Presence of radiographically measurable disease.
Is willing to provide tumor tissue
Has adequate organ function
Has a negative test or adequate therapy for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C.
Has completed all prior therapy.
Female subjects of childbearing potential must have a negative serum pregnancy test.
Both male and female subjects must be willing to use adequate contraception.

Exclusion Criteria:

Has peripheral neuropathy of Grade >1.
Has a malignancy involving the central nervous system.
Has another major cancer.
Has an uncontrolled ongoing infection.
Has significant cardiovascular disease.
Has a known diagnosis of liver cirrhosis.
Is pregnant or breastfeeding.
Has had major surgery within 4 weeks before the start of study therapy.
Has known tumor resistance or intolerance to a prior MMAE-containing drug.
Is concurrently participating in another therapeutic or imaging clinical trial.